TRIAL IN PROGRESS: AN INTRAVENOUSLY ADMINISTERED SECOND-GENERATION STING AGONIST, BI 1703880 WITH A NOVEL LEAD-IN DESIGN IN COMBINATION WITH EZABENLIMAB

Category Primary study
JournalJOURNAL FOR IMMUNOTHERAPY OF CANCER
Year 2022
This article has no abstract
Epistemonikos ID: 6d8e6422515ccc8829835c9cc24bd7da04c1d119
First added on: Feb 15, 2025